Study record
Urolithin A improves muscle strength and exercise performance in middle-aged adults (Singh et al., 2022)
Human RCT — functional endpoint
○ Evidence tier 3 — Human RCT — functional endpoint
Record verify: primary source pending
| Design | Randomized, double-blind, placebo-controlled trial (functional) |
| DOI | 10.1016/j.xcrm.2022.100633 |
| Citation status | doi verified via Crossref 2026-07-12 (Cell Rep Med 2022;3(5):100633, Singh et al., 'Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults'). PMID + NCT: needs_primary_fulltext. |
Five-qualifier claim
| Species / population | Middle-aged adults (randomized, placebo-controlled trial). |
| Exposure, route, schedule | Oral urolithin A (500 mg or 1000 mg/day) for 4 months. |
| Comparator / duration | Placebo-controlled, randomized, double-blind; 4-month intervention. |
| Endpoint / numeric result | Improved muscle strength (hamstring) and exercise/endurance performance, with changes in plasma mitochondrial biomarkers (e.g. acylcarnitines) and lower C-reactive protein. |
| What it did NOT establish | A functional-endpoint trial in middle-aged adults — not a lifespan, disease-outcome, or healthy-aging-longevity result. |
Interventions
Primary reference
https://doi.org/10.1016/j.xcrm.2022.100633
Exact identifier confirmed against the primary record via Crossref/ClinicalTrials.gov where stated in the citation status; anything marked needs_primary_fulltext is not yet confirmed.